Akeso Inc (9926)

Hong Kong
42.60
+1.50(+3.65%)
  • Volume:
    3,065,100
  • Bid/Ask:
    42.60/42.65
  • Day's Range:
    41.45 - 43.20

9926 Overview

Prev. Close
41.1
Day's Range
41.45-43.2
Revenue
157.19M
Open
41.9
52 wk Range
28-69.9
EPS
-1.42
Volume
3,065,100
Market Cap
33.58B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,539,494
P/E Ratio
-
Beta
-
1-Year Change
36.32%
Shares Outstanding
817,057,176
Next Earnings Date
-
What is your sentiment on Akeso Inc?
or
Market is currently closed. Voting is open during market hours.

  • Akeso Makes Soaring Hong Kong Debut
    • ByInvesting.com-
    • 3

    By Gina LeeInvesting.com – China’s Akeso Inc (HK:9926) made a splash as it debuted on the Hong Kong Stock Exchange, with its stock soaring up to HK$24.45 ($3.21).This is a 49%...

Akeso Inc Company Profile

Employees
1202
Market
Hong Kong

Akeso, Inc., a clinical-stage biopharmaceutical company, engages in research, development, discovery, manufacture, and commercialization of therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody for the treatment of cervical cancer, nasopharyngeal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, non-small cell lung cancer, and solid tumors; and Penpulimab AK105, a PD-1 monoclonal antibody for treating non-small cell lung cancer, classic Hodgkin’s lymphoma, nasopharyngeal cancer, hepatocellular carcinoma, gastric cancer, mismatch repair deficient solid tumor, small cell lung cancer, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, esophageal squamous cell carcinoma, urothelial carcinoma, gastroesophageal junction, cholangiocarcinoma, and neuroendocrine tumor. It is also developing AK119, a CD73 monoclonal antibody for the treatment of COVID-19 and solid tumors; AK109, a VEGFR-2 monoclonal antibody for treating solid tumors and gastric cancer; AK117, a CD47 monoclonal antibody for the treatment of solid tumors/lymphoma, myelodysplastic syndrome, and acute myeloid leukemia; and AK112, a PD-1/VEGF bi-specific antibody for the treatment of solid and gynecological tumors, non-small cell lung cancer, and small cell lung cancer. In addition, the company develops Ebronucimab (AK102), a PCSK9 monoclonal antibody for the treatment of hypercholesterolemia; AK120, an IL-4R monoclonal antibody for treating moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, a IL-12/IL-23 monoclonal antibody for the treatment of moderate-to-severe psoriasis and ulcerative colitis; and AK111, a IL-17 monoclonal antibody for treating moderate-to-severe psoriasis and ankylosing spondylitis. The company has collaboration agreements with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People’s Republic of China.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyNeutralSellBuy
Technical IndicatorsBuyStrong BuyStrong BuyStrong SellStrong Buy
SummaryBuyStrong BuyBuyStrong SellStrong Buy
  • UBS Initiates AKESO-B at Buy with $64.8 TP
    0
    • M Stanley Chops AKESO-B TP to $68.64; Rated Overweight
      0
      • AKESO-B Interim Loss Narrows to RMB425M
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.